Danish Commercial Services Stock News

Wondering if Novo Nordisk at DKK 265.8 still offers value, or if the best opportunity is already behind you? This article walks through what the current price actually reflects. The stock has moved sharply in the short term, with a 7.6% return over 7 days and 16.3% over 30 days, set against a year to date return of 19.5% decline and a 34.5% decline over the last year. These swings sit in the context of ongoing attention on Novo Nordisk's role in global pharmaceuticals, including regular...

Why Københavns Lufthavne Is On Investors’ Radar Københavns Lufthavne (CPSE:KBHL) has come into focus after a recent spell of weaker share performance, with negative returns over the past month, past 3 months and year prompting closer attention to its fundamentals. See our latest analysis for Københavns Lufthavne. With the share price at DKK5,880, Københavns Lufthavne has recorded a 6.67% decline over the past month and a 14.04% year-to-date share price retreat, alongside a 10.64% one-year...

For investors wondering whether ALK-Abelló’s current share price reflects its real worth or whether the market is getting ahead of itself, this breakdown focuses squarely on what you are paying versus what you are getting. With the stock at DKK 229.2 and returns of 2.7% over 7 days, 13.5% over 30 days, 1.1% year to date, 59.1% over 1 year, 167.0% over 3 years and 73.6% over 5 years, recent performance provides important context for any valuation view. Recent attention around ALK-Abelló has...

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after securing a 70 MW order from Tessa Green Energy for Bulgaria’s Strazhitsa wind project, paired with a long-term Active Output Management 5000 service agreement. See our latest analysis for Vestas Wind Systems. The new Bulgaria contract lands as Vestas’ share price trades at DKK192.0, with a 1 month share price return of 9.18% and a 1 year total shareholder return of 118.53%. This points to recent momentum following a mixed 3...

Why Carlsberg’s expanded PepsiCo partnership matters for shareholders Carlsberg (CPSE:CARL B) has agreed to expand its long running collaboration with PepsiCo, taking over bottling in Denmark, Finland and the Baltic states from 2029 as existing Coca-Cola arrangements conclude. For you as an investor, this shift means Carlsberg is set to handle production, sales and distribution of PepsiCo drinks across all Nordic markets, plus Latvia, Estonia and Lithuania. That extends an arrangement that...

Royal Unibrew A/S ( CPH:RBREW ) stock is about to trade ex-dividend in 2 days. The ex-dividend date generally occurs...

Earlier this month, Novo Nordisk reported positive Phase 3a PIONEER TEENS results showing its oral semaglutide cut HbA1c significantly versus placebo in 10–17-year-olds with type 2 diabetes, and said it plans to seek US and EU label expansions in the second half of 2026. By opening the door for the first oral GLP-1 therapy in youth-onset type 2 diabetes, Novo Nordisk is targeting a large, under-treated global patient group where current options like metformin and insulin have important...

H. Lundbeck (CPSE:HLUN B) shares are in focus after the company reported new 6 month real world INFUSE study results for migraine drug eptinezumab at the American Academy of Neurology 2026 meeting. See our latest analysis for H. Lundbeck. The eptinezumab data arrives at a time when H. Lundbeck’s short term momentum is positive, with a 14.59% 1 month share price return and a 54.44% 1 year total shareholder return. However, the 90 day share price return of 2.16% decline suggests some earlier...

Coloplast recently revised its FY 2025/26 guidance, trimming expected organic growth to 5–6% and EBIT growth to around 5%, while recording a DKK 3.00 billion goodwill impairment on Kerecis following sales disruption from a Medicare reimbursement change and softer skin substitutes demand. This combination of lower growth expectations and a large impairment charge highlights how reimbursement shifts in a single niche can materially affect Coloplast’s broader outlook and capital allocation...

Readers hoping to buy SP Group A/S ( CPH:SPG ) for its dividend will need to make their move shortly, as the stock is...

Zealand Pharma (CPSE:ZEAL) has been removed from multiple major S&P indices, affecting its presence in index-tracking portfolios. The index changes have already taken effect, altering how the company features in benchmark-based investment products. Separately, Zealand Pharma has appointed Eric Rojas as Vice President and Head of Investor Relations. Rojas brings experience in investor communications, with a mandate to lead the company’s engagement with the capital markets. Zealand Pharma...

Investors may be wondering whether Pandora's current share price reflects its true worth, or if the recent weakness has opened up a potential opportunity. The stock last closed at DKK 490.2, with returns of 1.9% over 30 days but declines of 4.7% over 7 days and 29.5% year to date, as well as 46.4% over 1 year. Recent coverage has focused on Pandora's share price performance and how the market is reassessing the business, with investors weighing current conditions against the company's long...

Recent share performance snapshot Pandora (CPSE:PNDORA) has drawn fresh attention after a recent pullback, with the share price down about 4.6% over the past day but slightly higher over the past month. Over the past 3 months, the stock shows a small decline, while year to date performance and the past year’s total return are both negative. This may prompt investors to reassess expectations and risk tolerance. See our latest analysis for Pandora. With the share price at DKK500.4, Pandora’s...

Royal Unibrew A/S has reported its Q1 2026 results, with sales rising to DKK 3,311 million and net income increasing to DKK 171 million, alongside basic and diluted earnings per share from continuing operations of DKK 3.5, all up from the same period last year. The company’s 25% EBIT increase, driven by margin expansion and market share gains while reaffirming its full-year 2026 outlook and running a share buyback program through August 14, 2026, highlights a focus on profitability and...

Wondering whether A.P. Møller - Mærsk is priced attractively right now, or if the recent run leaves less room for value focused investors. The share price closed at DKK 14,990, with a 1 year return of 43.3% and a 5 year return of 87.0%, while shorter term moves include a 7 day return of 5.9% decline and a 30 day return of 13.0% decline, with a 2.0% gain year to date. Recent share price moves sit against a backdrop of ongoing interest in global shipping and logistics, where investors continue...

DFDS (CPSE:DFDS) has raised its 2026 EBIT outlook to DKK 1,000 million to DKK 1,400 million after five of six key initiatives, led by the Mediterranean ferry network, performed ahead of expectations. See our latest analysis for DFDS. The raised 2026 EBIT outlook appears to have coincided with strong momentum in the shares, with a 30 day share price return of 53.91% and a 1 year total shareholder return of 77.57%, even though the 3 and 5 year total shareholder returns remain negative. If...

We'd be surprised if SKAKO A/S ( CPH:SKAKO ) shareholders haven't noticed that the MD, CEO & Non-Independent Director...

Recent performance snapshot for A.P. Møller - Mærsk (CPSE:MAERSK B) A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed share price returns, with a 1 day move of a 2.83% decline, a 7 day decline of 3.44%, a month decline of 11.27%, and a past 3 months gain of 3.98%. See our latest analysis for A.P. Møller - Mærsk. The recent 11.27% 1 month share price decline contrasts with a 4.02% year to date share price gain and a 46.06% 1 year total shareholder return, suggesting shorter term momentum has...

Genmab (CPSE:GMAB) has reported new clinical data for its antibody drug conjugate rinatabart sesutecan, known as Rina S, in advanced ovarian cancer. The therapy, in combination with bevacizumab, showed a tolerable safety profile with no new or unexpected safety signals in patients. The results were presented at a major oncology conference, adding fresh information on Genmab’s oncology pipeline. For investors tracking Genmab, the update on Rina S comes with the share price at DKK1,804.0 and...

Swiss Properties Invest A/S' ( CPH:SWISS ) stock wasn't much affected by its recent lackluster earnings numbers. We did...

Alm. Brand (CPSE:ALMB) has drawn attention after extending its collaboration with Ondo InsurTech’s LeakBot. The insurer plans to offer the leak detection device to up to 160,000 homeowners across its Danish insurance brands. See our latest analysis for Alm. Brand. The expanded LeakBot rollout and recent AGM decisions come after a weaker short term patch, with a 90 day share price return of 16.44% decline and year to date share price return of 17.74% decline, set against a 1 year total...

TORM plc ( CPH:TRMD A ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.

Readers hoping to buy Scandinavian Tobacco Group A/S ( CPH:STG ) for its dividend will need to make their move shortly...